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Abstract An efficient entry into highly substituted cyclopentanones is 
presented based on functionalizing cyclopentenones by means of an aza-
Michael reaction with different aniline nucleophiles. The excellent 
diastereoselectivity of this process is ascribed to H-bonding between a tertiary 
alcohol and the incoming nucleophiles. Additionally, the functionalization of 
the parent cyclopentenones via the Baylis-Hillman reaction is demonstrated. 
Together, these transformations showcase the elaboration of a simple 
precursor by installation of versatile functionalities at either the α- or β-
position of the embedded enone and thus represent valuable methods for the 
construction of diversely functionalized cyclopentanones.  
Key words cyclopentanone, aza-Michael reaction, Baylis-Hillman reaction, 
diastereoselectivity, H-bonding 
 
The efficient assembly of suitably functionalized three-
dimensional building blocks has in recent years gained increasing 
interest as it allows for the generation of structures occupying 
new chemical and biological space.1 Moreover, the sustainability 
of such processes is of increasing importance being a key feature 
that enables the reliable and future-proofed construction of such 
chiral building blocks.2 Together with the operational simplicity 
and robustness modern synthesis efforts aim to adhere to green 
chemistry principles whenever possible.3 In a recent synthesis 
program, we have for instance developed a flow process for 
converting bioderived D-glucono-1,5-lactone 1 into chiral 
cyclopentenone 4 in continuous mode (Scheme 1).4  
 
Scheme 1: Continuous flow synthesis of cyclopentenone 4. 
Highlights of this work included the application of powder dosing 
equipment and counter-current extraction modules allowing for 
the continuous production of 4 and selected key intermediates 
on large scale (>100 g). Furthermore, the successful implication 
of this route avoided the use of excessive or hazardous solvents 
and reagents as well as the need for chromatographic 
purifications. With a robust route to cyclopentenone 4 in hand we 
subsequently wished to study its conversion into further 
products of interest, especially those decorated with pendant 
amine functionalities. Crucially, we envisaged such amino-
hydroxy cyclopentanones to be worthwhile targets as related 
structures such as (–)-agelastatin A (5), pactamycin (6), or 
peramivir (7) are known to possess interesting biological 
properties. In addition, as highly efficient and modern routes 
towards such structures have been developed recently,5 
providing a rapid access to simplified derivatives is becoming 
equally desirable (Figure 1).  
 
Figure 1: Structures of bioactive cyclopentanes. 
We commenced our study by investigating the conjugate addition 
of different anilines 8 to cyclopentenone 4. Screening different 
solvents it was found that polar, aprotic solvents such as MeCN, 
dioxane or DMF were preferred over non-polar solvents (DCM, 
toluene, hexanes), especially when high concentrations of 2-4 M 
were employed. We thus opted for MeCN as a suitable and benign 
solvent and subsequently studied the effect of different 
temperatures keeping the concentration at 3 M throughout. It 
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was quickly established, that temperatures of 50-75°C gave full 
conversion within 6-12 h whereas lower temperatures 
significantly slowed down the reaction. We therefore identified 
ideal conditions to be the use of MeCN with high concentration of 
both substrates (4 and 8, 1:1 ratio, 3 M) at a reaction temperature 
of 70 °C (Scheme 2). 
Scheme 2: Optimized conditions for preparing aniline adducts. 
With these conditions in hand we next investigated the reaction 
of a series of anilines with substrate 4 aiming to establish the 
generality of this approach. We were thus pleased to see the 
smooth reaction of a variety of anilines under the established 
reaction conditions. As expected, electron-rich anilines gave 
faster reactions than neutral systems, whereas electron-poor 
anilines (R = CN, NO2) gave very low conversion (~10%) to the 
desired product after 12-24 h. It was also found that secondary 
anilines were poor reaction partners due to steric hindrance, 
typically resulting in low conversion only (5-10% after 24 h). 
Importantly, a variety of different substitution patterns on the 
arene moiety of primary anilines was tolerated allowing for the 
creation of diversely functionalized systems. In addition, 
heteroaryl amines such as those based on pyridines, as well as 
biaryl amines are well tolerated in this transformation furnishing 
the desired adducts in good to excellent isolated yields after 
purification via column chromatography (Scheme 3).   
 
Scheme 3: Substrate scope for products 9a-i. 
Crucially, these products were obtained as single diastereomers 
prompting us to investigate the origin of this stereoselectivity. 
We therefore crystallized products 9e and 9g allowing for single 
crystal diffraction experiments to be performed. These 
structures both indicate a syn-relationship between the tertiary 
alcohol and the amine functionality (Figure 2). 6  
Figure 2: X-ray structures of 9e (left) and 9g (right). 
We reasoned that this diastereoselectivity is the result of 
hydrogen bonding where the hydroxyl group directs the 
incoming amine nucleophile in a syn-fashion. It appears that this 
hydrogen bonding is not disturbed by additional hydrogen bond 
acceptors such as the pyridine nitrogen as evidenced in structure 
9g.  
Having accomplished the efficient functionalization of the β-
position of the cyclopentenone building block 4, we furthermore 
wished to establish whether the adjacent α-position is amenable 
to effective derivatization. To this end we opted to exploit the 
reaction of 4 with a small selection of benzaldehydes (10) via a 
Baylis-Hillman reaction. After screening different solvents, it was 
found that a mixture of chloroform and THF (1:1 v/v, 1.5 M) 
worked best in combination with DABCO as a catalyst (25 mol%) 
to give the desired reaction products 11 (Scheme 4). Using 1H-
NMR as a reliable technique to establish reaction progress 
allowed the identification of suitable conditions that promoted 
full conversion of all substrates within 10 h at 40 °C.  
Scheme 4: Baylis-Hillman reaction of 4 and benzaldehydes 10. 
Furthermore, we noticed that under the chosen reaction 
conditions cyclopentenone 4 is a fluctional species that 
undergoes additional transformations such as the formation of 
the isolable rearrangement structure 4c which likely results from 
an allylic transposition reaction of 4 via intermediate 4b (Scheme 
5).  
 
Scheme 5: Reaction pathways of cyclopentenone 4. 
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This material (4c) was identified based on a combination of 1H-
NMR and 13C-NMR techniques and did not form unless all 
components were present in the reaction mixture (4, 10 and 
DABCO). Based on this, we suggest a mechanism in which the 
aldehyde component is aiding in the allylic transposition by 
forming a covalent adduct 4a en route to intermediate 4b 
(Scheme 5). In addition, mixtures of 4 and 4c can be isolated after 
column chromatography for further analysis (see SI for details). 
However, as the desired Baylis-Hillman products 11 were 
obtained as principle products from this reaction, we surmise 
that 4b co-exists in an inconsequential equilibrium with 4 from 
which only 4 is partaking in the overall transformation. To 
confirm the connectivity of products 11 we secured an X-ray 
crystal structure of derivative 11a. In agreement with NMR-
spectroscopy the X-ray diffraction experiments confirmed that 
these products (11a-11d) are formed as mixtures of 
diastereoisomers (d.r. ~1:1)7 indicating that in this instance the 
more remote tertiary alcohol is not controlling the 
stereochemistry (Figure 3). 
 
Figure 3: Baylis-Hillman products and X-ray structure of 11 a. 
 
In summary, we have developed efficient routes for the 
functionalization of a versatile cyclopentenone building block 
that was previously accessed via a continuous flow sequence 
from D-glucono-1,5-lactone. Initially, we investigated the aza-
Michael addition of different anilines resulting in the 
diastereoselective formation of the corresponding adducts. We 
furthermore demonstrated the functionalization of the α-
position of the cyclopentenone substrate via a Baylis-Hillman 
reaction. Whereas the desired products were obtained as 
mixtures of diastereoisomers, we discovered a complementary 
allylic transposition pathway, that appears to be mediated by the 
aldehyde substrate which we will investigate in due course.  
 
The experimental section has no title; please leave this line here. 
Unless otherwise stated, all solvents were purchased from Fisher 
Scientific and used without further purification. Substrates and reagents 
were purchased from Alfa Aesar or Sigma Aldrich and used as received.  
1H-NMR spectra were recorded on a Bruker Avance-400 instrument and 
are reported relative to residual solvent: CHCl3 (δ 7.26 ppm) or DMSO (δ 
2.50 ppm). 13C-NMR spectra were recorded on the same instrument and 
are reported relative to CHCl3 (δ 77.16 ppm) or DMSO (δ 39.52 ppm). Data 
for 1H-NMR are reported as follows: chemical shift (δ/ ppm) (multiplicity, 
coupling constant (Hz), integration). Multiplicities are reported as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = 
multiplet, br. s = broad singlet, app = apparent. Data for 13C-NMR are 
reported in terms of chemical shift (δ/ ppm) and multiplicity (C, CH, CH2 
or CH3). Data for 19F-NMR were recorded on the above instrument at a 
frequency of 376 MHz using CFCl3 as external standard. DEPT-135, COSY, 
HSQC, HMBC and NOESY experiments were used in the structural 
assignment. IR spectra were obtained by use of a Perkin Elmer RX1 
spectrometer (neat, ATR sampling) with the intensities of the 
characteristic signals being reported as weak (w, <20% of tallest signal), 
medium (m, 21-70% of tallest signal) or strong (s, >71% of tallest signal). 
Low and high-resolution mass spectrometry was performed using the 
indicated techniques on either Waters LCT Premier XE or Waters TQD 
instruments equipped with Acquity UPLC and a lock-mass electrospray 
ion source. Melting points were recorded on an Optimelt automated 
melting point system with a heating rate of 1 °C/min and are uncorrected.   
 
Procedures 
For the synthesis of amino-hydroxycyclopentanones 9a-9i the desired 
aniline (1 mmol, 1.0 equiv.) was added to a solution of cyclopentanone 4 
(1 mmol, 1.0 equiv.; 2 M, MeCN). The resulting reaction mixture was 
heated at 75 °C and monitored by 1H-NMR. Once complete conversion of 
substrates was observed (6-12 h) the reaction mixture was evaporated 
and purified by silica column chromatography using EtOAc/hexanes (10-
30% EtOAc) as solvent system. After evaporation of the volatiles the 
desired products were typically isolated as yellow oils that solidified upon 
standing. 
Rac-(1S,2R)-Methyl 2-((4-chlorophenyl)amino)-1-hydroxy-4-
oxocyclopentanecarboxylate (9a) 
IR (neat): 3386 (m), 2955 (w), 1737 (s), 1599 (s), 1492 (s), 1398 (m), 
1316 (m), 1277 (m), 1234 (s), 1179 (s), 1091 (s), 1029 (m), 818 (s), 753 
(s), 501 (m) cm–1. 
1H NMR (CDCl3, 400 MHz):  = 7.10 (d, J = 8.9 Hz, 2H), 6.55 (d, J = 8.9 Hz, 
2H), 4.48 (dd, J = 10.9, 7.9 Hz, 1H), 3.88 (br s, 1H), 3.74 (s, 3H), 2.79-2.89 
(m, 2H), 2.61 (d, J = 18.2 Hz, 1H), 2.30 (ddd, J = 18.3, 10.9, 1.8 Hz, 1H). 
13C NMR (CDCl3, 101 MHz):  = 210.6 (C), 174.0 (C), 144.9 (C), 129.2 (2CH), 
123.4 (C), 115.1 (2CH), 78.7 (C), 57.4 (CH), 53.6 (CH3), 50.7 (CH2), 42.2 
(CH2). 
HRMS (ASAP): m/z [M + H]+ calcd for C13H15NO4Cl: 284.0690; found: 
284.0688. 
 
Rac-(1S,2R)-Methyl 2-((3-bromophenyl)amino)-1-hydroxy-4-
oxocyclopentanecarboxylate (9b) 
IR (neat): 3392 (m), 2955 (w), 1737 (s), 1595 (s), 1505 (m), 1481 (m), 
1266 (m), 1235 (s), 1198 (s), 1164 (s), 1089 (s), 987 (s), 756 (s), 734 (s), 
682 (m), 480 (m) cm–1. 
1H NMR (CDCl3, 400 MHz):  = 7.01 (t, J = 8.0 Hz, 1H), 6.86 (ddd, J = 7.8, 
1.8, 0.9 Hz, 1H), 6.77 (t, J = 2.1 Hz, 1H), 6.54 (ddd, J = 8.2, 2.4, 0.9 Hz, 1H), 
4.51 (dd, J = 11.0, 7.9 Hz, 1H), 4.26 (br s, 1H), 3.80 (s, 3H), 2.81-2.92 (m, 
2H), 2.62 (d, J = 18.2 Hz, 1H), 2.32 (ddd, J = 18.2, 10.9, 1.8 Hz, 1H). 
13C NMR (CDCl3, 101 MHz):  = 210.3 (C), 173.9 (C), 147.6 (C), 130.7 (CH), 
123.4 (C), 121.6 (CH), 116.3 (CH), 112.9 (CH), 78.6 (C), 56.9 (CH), 53.8 
(CH3), 50.6 (CH2), 42.3 (CH2). 
HRMS (ASAP): m/z [M + H]+ calcd for C13H15NO4Br: 328.0184; found: 
328.0172. 
 
Rac-(1S,2R)-Methyl 2-((4-bromophenyl)amino)-1-hydroxy-4-
oxocyclopentanecarboxylate (9c) 
IR (neat): 3476 (m), 3383 (m), 2957 (w), 1737 (s), 1593 (s), 1489 (s), 
1437 (m), 1397 (m), 1316 (m), 1278 (m), 1235 (s), 1179 (s), 1074 (m), 
908 (s), 815 (s), 728 (s), 648 (m), 499 (m) cm–1. 
1H NMR (CDCl3, 400 MHz):  = 7.26 (d, J = 8.0 Hz, 2H), 6.53 (d, J = 8.0 Hz, 
2H), 4.51 (app q, J = 8.7 Hz, 1H), 4.25 (d, J = 9.1 Hz, 1H), 3.83 (br s, 1H), 
3.78 (s, 3H), 2.83-2.92 (m, 2H), 2.64 (d, J = 18.3 Hz, 1H), 2.33 (ddd, J = 18.3, 
10.8, 1.8 Hz, 1H). 
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13C NMR (CDCl3, 101 MHz):  = 210.4 (C), 174.0 (C), 145.3 (C), 132.1 (2CH), 
115.6 (2CH), 110.5 (C), 78.7 (C), 57.2 (CH), 53.7 (CH3), 50.7 (CH2), 42.3 
(CH2). 
HRMS (AP): m/z [M + H]+ calcd for C13H15NO4Br: 328.0184; found: 
328.0193. 
 
Rac-(1S,2R)-Methyl 2-(m-tolylamino)-1-hydroxy-4-oxocyclo-
pentanecarboxylate (9d) 
IR (neat): 3391 (m), 2959 (w), 1739 (s), 1606 (m), 1490 (m), 1437 (m), 
1235 (m), 1167 (s), 1096 (m), 1030 (m), 909 (s), 772 (s), 728 (s), 692 (s), 
648 (m), 440 (m) cm–1. 
1H NMR (CDCl3, 400 MHz):  = 7.07 (app t, J = 7.6 Hz, 1H), 6.60 (d, J = 7.6 
Hz, 1H), 6.40-6.50 (m, 2H), 4.54 (app q, J = 10.0 Hz, 1H), 4.09 (d, J = 9.6 Hz, 
1H), 3.75 (s, 3H), 2.80-2.92 (m, 2H), 2.65 (d, J = 18.4 Hz, 1H), 2.32 (ddd, J 
= 18.4, 11.0, 1.8 Hz, 1H), 2.27 (s, 3H). 
13C NMR (CDCl3, 101 MHz):  = 210.8 (C), 174.1 (C), 146.2 (C), 139.2 (C), 
129.3 (CH), 119.8 (CH), 114.8 (CH), 111.1 (CH), 78.8 (C), 57.4 (CH), 53.5 
(CH3), 50.6 (CH2), 42.5 (CH2), 21.6 (CH3). 
HRMS (ES): m/z [M + H]+ calcd for C14H18NO4: 264.1236; found: 264.1237. 
 
Rac-(1S,2R)-Methyl 2-((3-methoxyphenyl)amino)-1-hydroxy-4-
oxocyclopentanecarboxylate (9e) 
IR (neat): 3437 (m), 3359 (m), 2963 (w), 1733 (s), 1595 (s), 1492 (m), 
1230 (s), 1172 (s), 1126 (s), 1026 (s), 973 (m), 839 (s), 774 (m), 756 (m), 
692 (m), 498 (m) cm–1. 
1H NMR (CDCl3, 600 MHz):  = 7.06 (app t, J = 8.2 Hz, 1H), 6.30 (ddd, J = 
8.2, 2.3, 0.8 Hz, 1H), 6.23 (ddd, J = 8.2, 2.3, 0.8 Hz, 1H), 6.18 (app t, J = 2.3 
Hz, 1H), 4.51 (app t, J = 9.4 Hz, 1H), 4.17 (s, 1H), 3.77 (s, 1H), 3.75 (s, 3H), 
3.74 (s, 3H), 2.82-2.88 (m, 2H), 2.61 (ddd, J = 18.2, 1.9, 0.8 Hz, 1H), 2.30 
(ddd, J = 18.2, 10.8, 1.9 Hz, 1H). 
13C NMR (CDCl3, 151 MHz):  = 210.7 (C), 174.1 (C), 160.8 (C), 147.5 (C), 
130.2 (CH), 106.8 (CH), 103.8 (CH), 100.2 (CH), 78.8 (C), 57.2 (CH), 55.1 
(CH3), 53.6 (CH3), 50.6 (CH2), 42.4 (CH2). 
HRMS (ES): m/z [M + H]+ calcd for C14H18NO5: 280.1185; found: 280.1163. 
 
Rac-(1S,2R)-Methyl 2-((4-chloro-2,5-dimethoxyphenyl)amino)-1-
hydroxy-4-oxocyclopentanecarboxylate (9f) 
IR (neat): 3395 (w), 2957 (w), 1747 (s), 1596 (m), 1515 (s), 1450 (s), 1398 
(s), 1207 (s), 1159 (s), 1031 (s), 910 (m), 848 (m), 796 (m), 728 (s), 649 
(m)cm–1. 
1H NMR (CDCl3, 400 MHz):  = 6.76 (s, 1H), 6.31 (s, 1H), 4.51 (dd, J = 11.1, 
7.9 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.70 (s, 3H), 2.78-2.91 (m, 2H), 2.65 
(ddd, J = 18.2, 1.8, 0.9 Hz, 1H), 2.32-2.43 (m, 1H). 
13C NMR (CDCl3, 101 MHz):  = 210.4 (C), 174.0 (C), 149.6 (C), 141.7 (C), 
135.5 (C), 112.4 (CH), 110.3 (C), 98.6 (CH), 78.7 (C), 57.8 (CH), 57.2 (CH3), 
56.2 (CH3), 53.5 (CH3), 50.6 (CH2), 42.4 (CH2). 
HRMS (ES): m/z [M + H]+ calcd for C15H19NO6Cl: 344.0901; found: 
344.0900. 
 
Rac-(1S,2R)-Methyl 2-((5-bromopyridin-3-yl)amino)-1-hydroxy-4-
oxocyclopentanecarboxylate (9g) 
IR (neat): 3358 (m), 2926 (m), 1739 (s), 1582 (s), 1518 (m), 1448 (m), 
1234 (s), 1201 (s), 1161 (s), 1095 (s), 1031 (m), 1006 (m), 753 (s), 695 
(m) cm–1. 
1H NMR (CDCl3, 400 MHz):  = 8.02 (d, J = 1.9 Hz, 1H), 7.92 (d, J = 2.6 Hz, 
1H), 7.07 (dd, J = 2.6, 1.9 Hz, 1H), 4.46-4.56 (m, 2H), 3.82 (s, 3H), 2.81-2.92 
(m, 2H), 2.64 (ddd, J = 18.2, 19, 0.9 Hz, 1H), 2.29-2.41 (m, 1H). 
13C NMR (CDCl3, 101 MHz):  = 209.6 (C), 173.7 (C), 143.5 (C), 140.2 (CH), 
134.9 (CH), 121.9 (CH), 121.1 (C), 78.6 (C), 56.4 (CH), 53.8 (CH3), 50.7 
(CH2), 42.0 (CH2). 
HRMS (ASAP): m/z [M + H]+ calcd for C12H14N2O4Br: 329.0137; found: 
329.0122. 
 
Rac-(1S,2R)-Methyl 2-((3-(6-methoxypyridin-3-yl)phenyl)amino)-
1-hydroxy-4-oxocyclopentanecarboxylate (9h) 
IR (neat): 3383 (w), 2952 (w), 1740 (s), 1604 (s), 1481 (s), 1366 (m), 1283 
(s), 1235 (s), 1173 (s), 1021 (s), 832 (m), 752 (s), 697 (m), 609 (m) cm–1. 
1H NMR (CDCl3, 400 MHz):  = 8.33 (dd, J = 2.6, 0.7 Hz, 1H), 7.72 (dd, J = 
8.6, 2.6 Hz, 1H), 7.21 (app t, J = 7.8 Hz, 1H), 6.85-6.90 (m, 1H), 6.73-6.80 
(m, 2H), 6.60 (ddd, J = 8.2, 2.4, 0.9 Hz, 1H), 4.60 (dd, J = 10.8, 7.8 Hz, 1H), 
4.41 (br s, 1H), 4.16 (br s, 1H), 3.67 (s, 3H), 3.67 (s, 3H), 2.82-2.94 (m, 2H), 
2.59-2.67 (m, 1H), 2.35 (ddd, J = 18.8, 10.8, 1.8 Hz, 1H). 
13C NMR (CDCl3, 101 MHz):  = 211.0 (C), 174.0 (C), 163.6 (C), 146.8 (C), 
144.9 (CH), 139.1 (C), 137.5 (CH), 130.1 (C), 130.0 (CH), 117.2 (CH), 112.9 
(CH), 112.2 (CH), 110.6 (CH), 78.9 (C), 57.3 (CH), 53.6 (CH3), 53.5 (CH3), 
50.7 (CH2), 42.3 (CH2). 
HRMS (ASAP): m/z [M + H]+ calcd for C19H21N2O5: 357.1450; found: 
357.1452. 
 
Rac-(1S,2R)-Methyl 2-((3-fluoro-4-methylphenyl)amino)-1-
hydroxy-4-oxocyclopentanecarboxylate (9i) 
IR (neat): 3384 (m), 2956 (w), 1736 (s), 1633 (s), 1589 (m), 1516 (s), 
1438 (m), 1326 (m), 1266 (m), 1235 (s), 1159 (s), 1114 (s), 1029 (m), 838 
(m), 803 (m), 735 (s), 626 (m), 454 (m) cm–1. 
1H NMR (CDCl3, 600 MHz):  = 6.90-6.96 (m, 1H), 6.29-6.33 (m, 2H), 4.46 
(ddd, J = 11.0, 10.0, 7.9 Hz, 1H), 4.11 (d, J = 8.8 Hz, 1H), 3.77 (s, 3H), 3.70 
(s, 1H), 2.82-2.88 (m, 2H), 2.61 (ddd, J = 18.3, 1.9, 0.9 Hz, 1H), 2.27-2.33 
(m, 1H), 2.13 (d, J = 1.3 Hz, 3H). 
13C NMR (CDCl3, 151 MHz):  = 210.3 (C), 174.0 (C), 161.9 (d, J = 243 Hz, 
C), 145.7 (d, J = 11 Hz, C), 131.9 (d, J = 8 Hz, CH), 114.5 (d, J = 18 Hz, C), 
109.7 (d, J = 2 Hz, CH), 100.9 (d, J = 26 Hz, CH), 78.6 (C), 57.4 (CH), 53.6 
(CH3), 50.6 (CH2), 42.3 (CH2), 13.6 (CH3). 
19F NMR (CDCl3, 376 MHz):  = -116.3 (s). 
HRMS (ASAP): m/z [M + H]+ calcd for C14H17NO4F: 282.1142; found: 
282.1158. 
 
Procedures 
For the synthesis of Baylis-Hillman adducts 11a-11d cyclopentenone 4 
(0.8 mmol, 1.0 equiv.), DABCO (0.2 mmol, 0.25 equiv.) and the aldehyde 
component (1.0 mmol, 1.25 equiv.) were dissolved in a mixture of THF 
and CHCl3 (1:1 v/v, 1.5 M) and stirred at 40 °C for 10 h. After completion 
of the reaction was indicated by tlc (20% EtOAc/hexanes) the solvents 
were evaporated and the crude product was purified by silica column 
chromatography 10-30% EtOAc/hexanes) to yield a mixture of co-polar 
reaction products. It was found possible to crystalize the less soluble 
diastereomer of 11 using CHCl3 or Et2O as solvent. 
Methyl 3-((4-bromophenyl)(hydroxy)methyl)-1-hydroxy-4-
cyclopent-2-enecarboxylate (11a) 
IR (neat): 3418 (br), 2956 (w), 1714 (s), 1488 (m), 1437 (m), 1402 (m), 
1258 (s), 1198 (s), 1171 (s), 1071 (s), 1011 (m), 832 (m) cm–1. 
Diastereomer A: 1H NMR (CDCl3, 400 MHz):  = 7.47 (d, J = 8.4 Hz, 2H), 7.25 
(d, J = 8.4 Hz, 2H), 6.98 (s, 1H), 3.81 (s, 3H), 2.98 (br s, 1H), 2.95 (d, J = 18.4 
Hz, 1H), 2.60 (d, J = 18.4 Hz, 1H). 13C NMR (CDCl3, 176 MHz):  = 203.9 (C), 
173.9 (C), 153.8 (CH), 149.2 (C), 139.1 (C), 131.8 (2CH), 128.3 (2CH), 
122.3 (C), 76.9 (C), 68.9 (CH), 54.0 (CH2), 48.3 (CH2). Diastereomer B: 1H 
NMR (CDCl3, 400 MHz):  = 7.47 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz, 2H), 
6.98 (s, 1H), 5.52 (s, 1H), 3.79 (s, 3H), 3.03 (br s, 1H), 2.92 (d, J = 18.4 Hz, 
1H), 2.65 (d, J = 18.4 Hz, 1H). 13C NMR (CDCl3, 176 MHz):  = 204.1 (C), 
173.8 (C), 154.2 (CH), 149.1 (C), 138.3 (C), 131.8 (2CH), 128.3 (2CH), 
122.3 (C), 77.0 (C), 68.9 (CH), 53.9 (CH3), 48.2 (CH2). 
HRMS (ASAP): m/z [M - OH]+ calcd for C14H12BrO4: 322.9919; found: 
322.9932. 
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Methyl 3-((3-fluorophenyl)(hydroxy)methyl)-1-hydroxy-4-
cyclopent-2-enecarboxylate (11b) 
IR (neat): 3424 (br), 2957 (w), 1711 (s), 1591 (m), 1487 (m), 1438 (m), 
1244 (s), 1198 (m), 1170 (m), 1082 (m),  911 (m), 789 (m), 758 (m), 731 
(m), 702 (m)cm–1. 
Diastereomer A: 1H NMR (CDCl3, 400 MHz):  = 7.29-7.35 (m, 1H), 7.13-
7.18 (m, 1H), 7.07 (dt, J = 9.7, 2.0 Hz, 1H), 6.97-7.03 (m, 2H), 5.96 (s, 1H), 
3.80 (s, 3H), 2.93 (d, J = 18.4 Hz, 1H), 2.65 (d, J = 18.4 Hz, 1H). 13C NMR 
(CDCl3, 101 MHz):  = 204.0 (C), 173.9 (C), 162.9 (CF, d, J = 244 Hz), 154.4 
(CH), 149.2 (C), 142.7 (C, d, J = 7 Hz), 130.3 (CH, d, J = 8 Hz), 122.4 (CH, d, 
J = 3 Hz), 115.2 (CH, d, J = 21 Hz), 113.6 (CH, d, J = 22 Hz), 77.1 (C), 68.8 
(CH, m), 54.0 (CH3), 48.2 (CH2). 19F NMR (CDCl3, 376 MHz):  = -112.4 (s). 
Diastereomer B: 1H NMR (CDCl3, 400 MHz):  = 7.29-7.35 (m, 1H), 7.13-
7.18 (m, 1H), 7.11 (dt, J = 9.7, 2.0 Hz, 1H), 6.97-7.03 (m, 2H), 5.98 (s, 1H), 
3.82 (s, 3H), 2.96 (d, J = 18.4 Hz, 1H), 2.62 (d, J = 18.4 Hz, 1H). 13C NMR 
(CDCl3, 101 MHz):  = 204.0 (C), 173.9 (C), 162.9 (CF, d, J = 244 Hz), 154.1 
(CH), 149.1 (C), 142.7 (d, J = 7 Hz), 130.3 (CH, d, J = 8 Hz), 122.2 (CH, d, J = 
3 Hz), 115.2 (CH, d, J = 21 Hz, 113.5 (CH, d, J = 22 Hz), 77.2 (C), 68.8 (CH, 
m), 54.0 (CH3), 48.3 (CH2). 19F NMR (CDCl3, 376 MHz):  = -112.2 (s).   
HRMS (ES): m/z [M - OH]+ calcd for C14H12FO4: 263.0714; found: 
263.0737. 
 
Methyl 1-hydroxy-3-(hydroxy(2-methoxypyrimidin-5-yl)methyl)-4-
oxocyclopent-2-enecarboxylate (11c) 
IR (neat): 3457 (m), 3171 (br), 1741 (s), 1713 (s), 1600 (m), 1570 (m), 
1478 (s), 1407 (s), 1331 (m), 1272 (s), 1197 (m), 1168 (m), 1031 (s), 804 
(m) cm–1. 
Diastereomer A: 1H NMR (CDCl3, 400 MHz):  = 8.53 (s, 2H), 7.12 (d, J = 1.4 
Hz, 1H), 5.60 (d, J = 1.4 Hz, 1H), 4.01 (s, 3H), 3.84 (s, 3H), 2.99 (d, J = 18.4 
Hz, 1H), 2.64 (d, J = 18.4 Hz, 1H), 2.17 (br s, 1H). 13C NMR (CDCl3, 101 
MHz):  = 203.8 (C), 173.7 (C), 165.5 (C), 158.1 (2CH), 154.2 (CH), 148.3 
(C), 127.1 (C), 77.2 (C), 65.6 (CH), 55.2 (CH3), 54.1 (CH3), 48.3 (CH2). 
Diastereomer B: 1H NMR (CDCl3, 400 MHz):  = 8.48 (s, 2H), 7.24 (s, 1H), 
5.56 (s, 1H), 3.99 (s, 3H), 3.79 (s, 3H), 3.20 (br s, 2H), 2.93 (d, J = 18.4 Hz, 
1H), 2.66 (d, J = 18.4 Hz, 1H). 13C NMR (CDCl3, 101 MHz):  = 203.6 (C), 
173.6 (C), 165.3 (C), 158.2 (2CH), 154.6 (CH), 148.7 (C), 127.3 (C), 77.2 
(C), 65.1 (CH), 55.2 (CH3), 54.0 (CH3), 48.3 (CH2). 
HRMS (ES): m/z [M + H]+ calcd for C13H15N2O6: 295.0930; found: 
295.0932. 
 
Methyl 1-hydroxy-3-(hydroxy(2,3,6-trichlorophenyl)methyl)-4-
oxocyclopent-2-enecarboxylate (11d) 
IR (neat): 3421 (br), 2956 (w), 1712 (s), 1436 (s), 1322 (m), 1249 (s), 
1192 (s), 1172 (s), 1092 (s), 1025 (m), 1010 (m), 913 (m), 912 (s), 771 
(m), 731 (s) cm–1. 
Diastereomer A: 1H NMR (CDCl3, 400 MHz):  = 7.39 (d, J = 8.7 Hz, 1H), 7.28 
(d, J = 8.7 Hz, 1H), 7.14 (d, J = 2.1 Hz, 1H), 6.39 (d, J = 5.2 Hz, 1H), 3.81 (s, 
3H), 3.79 (s, 1H), 3.61 (d, J = 7.0 Hz, 1H), 2.95 (d, J = 18.3 Hz, 1H), 2.68 (d, 
J = 18.3 Hz, 1H). 13C NMR (CDCl3, 101 MHz):  =
 202.9 (C), 174.0 (C), 154.8 
(CH), 146.8 (C), 136.6 (C), 133.7 (C), 133.5 (C), 132.9 (C), 130.6 (CH), 129.5 
(CH), 76.8 (C), 68.1 (CH), 53.9 (CH3), 48.2 (CH2). Diastereomer B: 1H NMR 
(CDCl3, 400 MHz):  = 7.32 (d, J = 8.7 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 7.20 
(d, J = 2.1 Hz, 1H), 6.29 (d, J = 2.0 Hz, 1H), 4.11 (br s, 2H), 3.74 (s, 3H), 2.90 
(d, J = 18.4 Hz, 1H), 2.59 (d, J = 18.4 Hz, 1H). 13C NMR (CDCl3, 101 MHz):  
= 203.0 (C), 173.8 (C), 155.4 (CH), 147.0 (C), 136.4 (C), 133.7 (C), 132.8 
(C), 130.5 (CH), 129.4 (CH), 77.0 (C), 67.7 (CH), 53.7 (CH3), 48.2 (CH2).  
HRMS (ASAP): m/z [M - OH]+ calcd for C14H10Cl3O4: 346.9645; found: 
346.9650. 
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